Oberlander Tim F, Warburton William, Misri Shaila, Aghajanian Jaafar, Hertzman Clyde
Department of Pediatrics, Human Early Learning Partnership, Faculty of Graduate Studies, University of British Columbia, Vancouver.
Arch Gen Psychiatry. 2006 Aug;63(8):898-906. doi: 10.1001/archpsyc.63.8.898.
Prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants and maternal depression both alter neonatal health, and distinguishing the effects of each influence remains challenging.
To determine whether exposure to SSRIs and depression differs from exposure to maternal depression alone.
Using population health data, records of neonatal birth outcomes were linked to records of maternal health and prenatal maternal prescriptions for SSRIs.
Population of British Columbia, Canada.
Mothers and their infants, representing all live births during a 39-month period (N = 119,547) (1998-2001).
Outcomes from infants of depressed mothers treated with SSRIs (SE-D) were compared with outcomes from infants of depressed mothers not treated with medication (DE) and nonexposed controls. To control for maternal mental illness severity, propensity score matching was used to identify a comparison group of DE mothers who were similar to the SE-D mothers in characteristics in the year preceding and during pregnancy.
Fourteen percent of mothers were diagnosed as having depression during their pregnancy, and the incidence of prenatal SSRI exposure increased from 2.3% to 5.0% during a 39-month period. Birth weight and gestational age for SE-D infants were significantly less than for DE infants, as was the proportion of infants born at less than 37 weeks (95% confidence interval [CI], -1 to -64, -0.25 to -0.45, and -0.009 to -0.04, respectively), although differences in the incidence of birth weight less than the 10th percentile for gestational age were not significant. An increased proportion of SE-D infants had neonatal respiratory distress (13.9% vs 7.8%), jaundice (9.4% vs 7.5%), and feeding problems (3.9% vs 2.4%) compared with DE infants (95% CI of difference, 0.042-0.079, 0.003-0.334, and 0.005-0.025, respectively). When outcomes were compared between SE-D and propensity score-matched DE neonates, SE-D was associated with increased incidence of birth weight below the 10th percentile and rates of respiratory distress.
With linked population health data and propensity score matching, prenatal SE-D exposure was associated with an increased risk of low birth weight and respiratory distress, even when maternal illness severity was accounted for.
产前暴露于选择性5-羟色胺再摄取抑制剂(SSRI)类抗抑郁药以及母亲抑郁都会改变新生儿健康状况,区分各自影响仍具有挑战性。
确定暴露于SSRI类药物和抑郁与单独暴露于母亲抑郁的影响是否不同。
利用人群健康数据,将新生儿出生结局记录与母亲健康记录以及母亲产前SSRI类药物处方记录相联系。
加拿大不列颠哥伦比亚省人群。
母亲及其婴儿,代表39个月期间(1998 - 2001年)的所有活产儿(N = 119,547)。
将接受SSRI治疗的抑郁母亲的婴儿(SE-D)的结局与未接受药物治疗的抑郁母亲的婴儿(DE)以及未暴露对照组的结局进行比较。为控制母亲精神疾病严重程度,采用倾向评分匹配法确定一组在妊娠前及妊娠期间特征与SE-D母亲相似的DE母亲作为对照组。
14%的母亲在孕期被诊断为抑郁,在39个月期间产前SSRI暴露发生率从2.3%升至5.0%。SE-D婴儿的出生体重和孕周显著低于DE婴儿,孕周小于37周出生的婴儿比例也是如此(95%置信区间[CI]分别为 -1至 -64、-0.25至 -0.45以及 -0.009至 -0.04),尽管出生体重低于孕周第10百分位数的发生率差异不显著。与DE婴儿相比,SE-D婴儿出现新生儿呼吸窘迫(13.9%对7.8%)、黄疸(9.4%对7.5%)和喂养问题(3.9%对2.4%)的比例增加(差异的95% CI分别为0.042 - 0.079、0.003 - 0.334以及0.005 - 0.025)。当比较SE-D和倾向评分匹配的DE新生儿的结局时,SE-D与出生体重低于第10百分位数的发生率增加以及呼吸窘迫发生率增加相关。
通过关联人群健康数据和倾向评分匹配,即使考虑了母亲疾病严重程度,产前SE-D暴露仍与低出生体重和呼吸窘迫风险增加相关。